Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review.
Cedric PobelEdouard AuclinAdrien ProcureurAlice Clément-ZhaoAudrey SimonaggioNicolas DelanoyYann-Alexandre VanoConstance ThibaultStéphane OudardPublished in: Future oncology (London, England) (2020)
Cabazitaxel (25 mg/m2 every 3 weeks) is the standard second-line chemotherapy for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. It is associated with a risk of neutropenic complications, which may be a barrier to its use in daily clinical practice, particularly in frail elderly patients. Here the authors reviewed key studies conducted with cabazitaxel (TROPIC, PROSELICA, AFFINITY, CARD and the European compassionate use program) and pilot studies with adapted schedules. Based on this review, the use of prophylactic granulocyte colony-stimulating factor from cycle 1 appears crucial to maximize the benefit-risk ratio of cabazitaxel in metastatic castration-resistant prostate cancer. Preliminary data with alternative schedules look promising, especially for frail patients. Results of the ongoing Phase III CABASTY trial (ClinicalTrials.gov: NCT02961257) are awaited.
Keyphrases
- phase iii
- clinical trial
- open label
- squamous cell carcinoma
- clinical practice
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- phase ii
- study protocol
- chronic kidney disease
- locally advanced
- randomized controlled trial
- physical activity
- double blind
- quality improvement
- prognostic factors
- peritoneal dialysis
- radiation therapy
- artificial intelligence
- risk factors
- preterm birth